Bivictrix granted FDA orphan drug status for rare cancer treatment
17th Apr 2024 14:23
(Alliance News) - Bivictrix Therapeutics PLC on Wednesday said its BVX001 drug has been granted special status by the US Food and Drug Administration. Read More
| Price | 11.50p on 19-04-2024 at 16:30:03 |
|---|---|
| Change | 0.00p 0% |
| Buy | 12.00p |
| Sell | 11.00p |
| Buy / Sell BVX Shares | |
| Last Trade: | Unknown 91,694.00 at 11.03p |
| Day's Volume: | 0 |
| Last Close: | 11.50p |
| Open: | 11.50p |
| ISIN: | GB00BNXH3K91 |
| Day's Range | 11.50p - 11.50p |
| 52wk Range: | 9.00p - 15.90p |
| Market Capitalisation: | £9m |
| VWAP: | 0.00p |
| Shares in Issue: | 83m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Recent Trades History Bivictrix Thera (BVX) |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 91,694 | 11.03p | Ordinary |
11:12:34 - 18-Apr-24 |
| Unknown* | -91,964 | 11.03p | Ordinary Correction |
11:12:34 - 18-Apr-24 |